

Resource Summary Report

Generated by [RRID](#) on Aug 14, 2026

DC-SIGN antibody [5D7]

RRID:AB_940866

Type: Antibody

Proper Citation

Abcam Cat# ab59192, RRID:AB_940866

Antibody Information

URL: http://antibodyregistry.org/AB_940866

Proper Citation: Abcam Cat# ab59192, RRID:AB_940866

Target Antigen: DC-SIGN antibody [5D7]

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: IHC-FoFr, IHC-P, WB; Immunohistochemistry; Immunohistochemistry - frozen; Western Blot; Immunohistochemistry - fixed

Antibody Name: DC-SIGN antibody [5D7]

Description: This monoclonal targets DC-SIGN antibody [5D7]

Target Organism: human

Antibody ID: AB_940866

Vendor: Abcam

Catalog Number: ab59192

Record Creation Time: 20250819T210234+0000

Record Last Update: 20250819T213930+0000

Ratings and Alerts

No rating or validation information has been found for DC-SIGN antibody [5D7].

No alerts have been found for DC-SIGN antibody [5D7].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chaudhary R, et al. (2025) Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research.

Wu RQ, et al. (2023) Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma. Immunity, 56(1), 180.